Cleo Diagnostics Ltd (ASX:COV)

Cleo Diagnostics Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023
Other Revenue	2.56	0.85	0.21	-
Revenue	2.56	0.85	0.21	-
Revenue Growth (YoY)	1115.45%	300.91%	-	-
Gross Profit	2.56	0.85	0.21	-
Selling, General & Admin	2.48	1.88	1.1	1.37
Research & Development	3.8	2.88	2.57	0.25
Other Operating Expenses	0.1	0.1	0.12	0.04
Operating Expenses	6.44	4.93	3.85	1.7
Operating Income	-3.87	-4.08	-3.64	-1.7
Interest Expense	-	-	-0.03	-0.11
Interest & Investment Income	0.24	0.34	0.39	-
Other Non Operating Income (Expenses)	-0.4	-0.26	-0.48	0.08
Pretax Income	-4.03	-4	-3.76	-1.73
Net Income	-4.03	-4	-3.76	-1.73
Net Income to Common	-4.03	-4	-3.76	-1.73
Shares Outstanding (Basic)	129	129	117	26
Shares Outstanding (Diluted)	129	129	117	26
Shares Change (YoY)	10.54%	9.53%	346.76%	-
EPS (Basic)	-0.03	-0.03	-0.03	-0.07
EPS (Diluted)	-0.03	-0.03	-0.03	-0.07
Free Cash Flow	-2.52	-2.91	-2.03	-0.72
Free Cash Flow Per Share	-0.02	-0.02	-0.02	-0.03
Gross Margin	100.00%	100.00%	100.00%	-
Operating Margin	-151.15%	-483.01%	-1727.45%	-
Profit Margin	-157.36%	-473.17%	-1783.22%	-
Free Cash Flow Margin	-98.35%	-344.57%	-964.47%	-
EBITDA	-3.81	-4.02	-3.58	-1.66
D&A For EBITDA	0.06	0.06	0.06	0.04
EBIT	-3.87	-4.08	-3.64	-1.7

Source: S&P Global Market Intelligence. Standard template. Financial Sources.